Melatonin (2015) for Central Serous Chorioretinopathy (CSR)
Learn more about central serous choroidopathy (CSR).
Researchers investigated whether melatonin could have therapeutic benefit for patients with CSR. CSR is a condition characterized by rapid onset of blurry vision and other symptoms in one eye in men aged 20-50.
In this small study 8 patients with CSR were treated with melatonin for a month and 5 control patients were treated with placebo. Prior to the trial all of the patients were given standard vision acuity tests and the thickness of the center of the macula was measured.
After a month 7 out of 8 of the patients had improved vision according to standard tests. Three out of the 5 patients had complete resolution. There were no changes for the control group.
The improvements were in both better vision acuity and better macular thickness as measured through standard testing.
The researchers concluded that melatonin is both safe and effective as a treatment for this condition.
Researchers: A. J. Gramajo, G. E. Marquez, et al.
Published: Therapeutic benefit of melatonin in refractory central serous chorioretinopathy, Eye, August, 2015.